Current and Future Perspectives in the Treatment of High-risk MDS
 | Current and Future Perspectives in the Treatment of High-risk MDS CME, CPE Richard Stone, MD | |
| Release Date: May 31, 2021 Expiration Date: May 31, 2022 | ||
Join Dr. Richard Stone as he explores current and future treatments for high-risk myelodysplastic syndromes (MDS). Topics will include risk assessment and stratification systems, venetoclax as monotherapy or in combination with hypomethylating agents, the implications of TP53 mutations, and the role of investigational agents in high-risk MDS, including oral cedazuridine/decitabine, enasidenib, pevonedistat, APR-246, magrolimab, and sabatolimab. Provided by MediCom Worldwide, Inc.This activity is supported by educational grants from Bristol-Myers Squibb and Taiho Oncology, Inc. | ||
| Begin, Earn CreditView Only, No Credit | ||